Royal Bank of Canada
KYTX icon

Royal Bank of Canada’s Kyverna Therapeutics KYTX Stock Holding History

Royal Bank of Canada’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$23K Sell
2,548
-716
-22% -$5.97K ﹤0.01% 5848
2025
Q4 		$30K Buy
3,264
+1,243
+62% +$9.23K ﹤0.01% 5832
2025
Q3 		$12K Buy
2,021
+1,079
+115% +$4.31K ﹤0.01% 6434
2025
Q2 		$3K Buy
942
+199
+27% +$492 ﹤0.01% 6764
2025
Q1 		$1K Sell
743
-856
-54% -$2.53K ﹤0.01% 6730
2024
Q4 		$6K Sell
1,599
-462
-22% -$2.21K ﹤0.01% 6510
2024
Q3 		$10K Buy
2,061
+477
+30% +$3.68K ﹤0.01% 6347
2024
Q2 		$12K Buy
1,584
+1,580
+39,500% +$24.1K ﹤0.01% 6281
2024
Q1 		$0 Buy
+4
New +$112 ﹤0.01% 7696

Other funds holding KYTX

GGI
GordonMD Global Investments Beverely Hills, California $144M AUM
GS
Gilead Sciences Foster City, California $1.65B AUM 166.99% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
IHG
Insight Holdings Group New York $1.42B AUM 41.03% 1-Year Est. Return

Royal Bank of Canada's KYTX Position: Q1 2026 in Review

Royal Bank of Canada reduced its Kyverna Therapeutics (KYTX) stake by 22% in Q1 2026, selling an estimated $5.97K and leaving 2,548 shares worth $23K. The position accounts for ﹤0.01% of the portfolio, ranked #5848.

Royal Bank of Canada first reported a position in KYTX in Q1 2024 and has held it in 9 quarters since. The position peaked at $30K in Q4 2025. 111 funds tracked by Wall St. Rank hold KYTX as of Q1 2026.

  • Royal Bank of Canada held 2,548 shares of Kyverna Therapeutics worth $23K as of Q1 2026.
  • Royal Bank of Canada sold 716 Kyverna Therapeutics shares in Q1 2026, an estimated $5.97K.
  • Kyverna Therapeutics made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #5848 holding.
  • Royal Bank of Canada first reported a position in Kyverna Therapeutics in Q1 2024 and has held it in 9 quarters since.
  • Royal Bank of Canada's Kyverna Therapeutics position peaked at $30K in Q4 2025.
  • 111 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.